Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01020890
First received: November 25, 2009
Last updated: July 9, 2010
Last verified: July 2010
  Purpose

The purpose of this study is to provide data on the gastroesophageal reflux disease (GERD) prevalence as percentage of patients with upper gastrointestinal (GI) symptoms that are identified with GERD using the Gerd-Q Questionnaire.


Condition
Gastroesophageal Reflux Disease

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: A Cross-sectional Study on the Prevalence of GERD in Primary Care Patients With Upper GI Symptoms Using the GERD-Q. The Bulgarian GERD-Q Study

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 2210
Study Start Date: November 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Primary care clinic

Criteria

Inclusion Criteria:

  • Patients with upper gastrointestinal symptoms

Exclusion Criteria:

  • History of oesophageal, gastric or duodenal surgery
  • Current treatment with antiinflammatory drugs, including OTC
  • Current treatment with proton pump inhibitors ang H2-blockers
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01020890

Locations
Bulgaria
Research Site
Blagoevgrad, Bulgaria
Research Site
Burgas, Bulgaria
Research Site
Dobrich, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Russe, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Veliko Turnovo, Bulgaria
Research Site
Vratsa, Bulgaria
Research Site
Yambol, Bulgaria
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01020890     History of Changes
Other Study ID Numbers: NIS-GBG-NEX-2009/1
Study First Received: November 25, 2009
Last Updated: July 9, 2010
Health Authority: Bulgaria: Ministry of Health

Keywords provided by AstraZeneca:
GERD diagnosis
GERD-Q
GERD patients' characteristics
GERD

Additional relevant MeSH terms:
Gastroesophageal Reflux
Gastrointestinal Diseases
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 23, 2014